Hormonal
Obesity induces a state of chronic low-grade systemic inflammation driven by adipose tissue macrophage infiltration and pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β), which contributes to insulin resistance and metabolic disease.
Obesity is not just about weight; it triggers a biological inflammatory response that harms metabolic health. Managing weight through diet and exercise can reduce this inflammation and lower the risk of diseases like diabetes and heart disease.
In overweight and obesity, there exists low-grade chronic inflammation... The main source of pro-inflammatory cytokines in obesity is the adipose tissue; they are mainly produced by infiltrating macrophages... The main cytokines responsible of chronic inflammation are tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and the inflammasome-activated IL-1β mentioned earlier.
Why this rating
The paper is a review citing numerous observational and interventional studies, establishing strong consensus on the association, though specific causal interventions are less detailed.
Source
Obesity and Inflammation: Epidemiology, Risk Factors, and Markers of Inflammation
Heriberto Rodríguez-Hernández et al. · International Journal of Endocrinology · 2013
DOI 10.1155/2013/678159
More from this paper
- Weight loss interventions, including dietary changes and physical activity, reduce circulating levels of pro-inflammatory markers (CRP, IL-6, TNF-α) in obese individuals.Good
- Mediterranean diet patterns, rich in fruits, vegetables, and monounsaturated fats, reduce the prevalence of metabolic syndrome and lower inflammatory markers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →